Jason Slakter, MD
Chief Executive Officer
Dr. Slakter joined Ohr as Chief Medical Officer in May 2014 and was appointed board member in January 2015. He was previously Chief Executive Officer and co-founder of SKS Ocular LLC. He is also the Founder and Director of the Digital Angiography Reading Center (DARC) in New York, which is the largest center for ocular image evaluation for clinical trials of posterior segment disease with over 900 certified clinical sites in over 44 countries worldwide. Dr. Slakter has been involved extensively in the design and application of new diagnostic and treatment modalities for ophthalmic diseases. He has played a major role in the discovery, development and commercialization of treatments for age-related macular degeneration, diabetic retinopathy, retinal vascular disease, central serous chorioretinopathy and other retinal diseases. He has provided critical assistance in the design of clinical trials at all stages of development, and has participated in numerous meetings with the FDA.
Dr. Slakter served as Chief Medical Officer for Potentia Pharmaceuticals from its inception through its acquisition by Alcon Laboratories, Inc. (Novartis). Dr. Slakter is a member of The American Ophthalmological Society, The Macula Society, The Retina Society, and The American Society of Retina Specialists, and was the founder and first Editor-in-Chief of Retinal Physician journal. He has been the recipient of many awards including The Macula Society's Richard and Hinda Rosenthal Award for outstanding contribution to the treatment of ocular disease by an individual under the age of 45, the 2003 Helen Keller Manhattan League Award, and Senior Honor Award from the American Academy of Ophthalmology. Dr. Slakter is a Clinical Professor of Ophthalmology at New York University School of Medicine and has also practiced at the Vitreous-Retina-Macula Consultants of New York for over 26 years.
Chief Financial Officer and Vice President of Business Development
Mr. Backenroth has executive experience in advising and financing biotechnology companies. He previously worked as an Investment Banker with The Benchmark Company LLC, an Investment Banking firm specializing in micro-cap biotechnology transactions. While at Benchmark, Sam helped fund numerous small biotechnology companies raise equity growth capital through a variety of structures. Mr. Backenroth also acted as an advisor to multiple public and private biotechnology and pharmaceutical companies in assisting with business development activities, joint ventures, licensing, strategic partnerships, and mergers & acquisitions. He graduated with honors from Touro College with a Bachelor's degree in finance.
Glenn L. Stoller, MD
Chief Scientific Officer
Dr. Glenn L. Stoller is a nationally recognized retina specialist, medical scientist and innovator. He was previously Chief Scientific Officer and cofounder of SKS Ocular LLC. He has participated in all stages of preclinical and clinical development for therapeutics and devices as well as and post-approval sales and marketing. As a principal investigator, pharmaceutical industry consultant, and scientific advisory board member, he has participated in over 40 clinical trials for ocular diseases including wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and retinal venous occlusive disease. Dr. Stoller led Lpath Ocular and oversaw the preclinical and clinical development of iSONEP, from inception through a development and commercialization partnership with Pfizer. He led the non-GLP and IND enabling studies for iSONEP leveraging relationships with biotech companies, contract research organizations, and academia. He was actively involved in all aspects of the iSONEP ocular program, including formulation, toxicology and CMC. He played a key role in the design and development of clinical protocols and presentation of the program to the FDA. Dr. Stoller currently serves as a member of the Pfizer-Lpath Joint Development Committee. He played a key role in establishing that bioactive lipids are mediators of human retinal disease. He is a member of the major medical organizations in his field including The Retina Society and The American Society of Retina Specialists. He is currently a Steering Committee Member of the American Academy of Ophthalmology’s Ophthalmic Registry Work Group where he serves as the sole representative for The Macula Society, The Retina Society and The American Society of Retina Specialists. He has served as Editorial Board Member of The American Academy Of Ophthalmology.
Peter K. Kaiser, MD
Head of Product Development
Dr. Peter K. Kaiser is an internationally recognized vitreoretinal specialist and a leader in ophthalmic pharmaceutical development. He was previously Chief Medical Officer and cofounder of SKS Ocular LLC. Dr. Kaiser has been a principal investigator in over 50 trials evaluating new treatments for AMD, DR, and other retinal disorders, and Study Chairman of 7 major, multi-center, international clinical trials. He has participated in the preparation of regulatory filings and presentations to the FDA for Regeneron, and Thrombogenics. Dr. Kaiser is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR), which is the OCT coordinating center for numerous multicenter clinical trials. He serves on the scientific advisory boards of Bayer, Novartis, Digisight, Genentech, GlaxoSmithKline, Allegro, Alcon, Allergan, Regeneron, Bausch and Lomb, Thrombogenics, Alimera, Oraya, Ophthotech, and Kanghong. He is a National Institute of Health RO1 funded investigator and leads a team involved in the evaluation of vascular biology in age-related macular degeneration and diabetic retinopathy. He has authored six ophthalmology textbooks, and more than 200 peer-reviewed papers. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of American Journal of Ophthalmology, Retina, Retina Today, and Ocular Surgery News. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with both Achievement and Senior Achievement Awards.
Marlene Modi, Ph.D.
Head of Preclinical and Regulatory Affairs
Marlene Modi serves as Vice President of Preclinical Development and Regulatory Affairs at Ohr Pharmaceutical, Inc. She has more than 25 years of experience in the pharmaceutical industry. Previously, she was Vice President of Preclinical Development at Optherion, Inc. and Senior Director of Clinical Pharmacology at Eyetech Pharmaceuticals, Inc with responsibilities for assessing the pharmacology and toxicology of compounds in development. For 15 years, Dr. Modi worked at Hoffmann-La Roche in key management positions, including Site Head and Director of Clinical Pharmacology. Dr. Modi has extensive expertise in the areas of preclinical and clinical development of large molecules (e.g., proteins, monoclonal antibodies, aptamers and pegylated compounds). She has facilitated the IND submission of more than 14 compounds within the last 5 years. She has played a key role in the submissions of NDAs/BLAs/MAAs and sNDAs including Pegasys®, CoPegasus® and Macugen®. Her work has included the therapeutic areas of ophthalmology, virology, infectious disease, neurology, oncology, diabetes and asthma. Her areas of expertise include drug-drug interactions, pharmacokinetic-pharmacodynamic relationships, ocular and intraocular formulation development, and dose- and exposure-response relationships in special populations. She received a B.S. in Pharmacy from the University of Houston and a Ph.D. in Pharmaceutics from the State University of New York at Buffalo.